Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array.
Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array.
复制标题
DOI：
10.1016/j.bios.2010.02.009
复制
发表时间：
2011-01-15
影响因子：
12.6
通讯作者：
Ratliff TL
中科院分区：
文献类型：
--
作者：
Wang X;Zhao M;Nolte DD;Ratliff TL
用于蛋白质检测的无荧光生物传感器阵列直接测量蛋白质表面密度，不需要荧光团或酶标记，并提供定量和一致的信号。然而，由于非特异性结合，很少有无荧光生物传感器蛋白阵列在高背景样品（如血清）中成功应用。我们将BioCD作为一种基于光学干涉法的无荧光生物传感器进行了测试，并在96孔抗PSA微阵列中检测了患者血清中的前列腺特异性抗原（PSA，前列腺癌的生物标志物）。我们在血清中达到了4 ng/ml的检测限，并测量了患者血清中的PSA浓度。测定的浓度与酶联免疫吸附试验（ELISA）结果具有良好的相关性。高水平蛋白质背景下PSA浓度的测量表明，通过消除高背景应用中无荧光生物传感器的限制，BioCD具有临床应用的潜力。
Fluorescence-free biosensor arrays for protein detection directly measure the protein surface density, and do not require a fluorophore or enzyme label, and provide quantitative and consistent signals. However, few fluorescence-free biosensor protein arrays have demonstrated successful application in high-background samples, such as serum, due to non-specific binding. We tested the BioCD as a fluorescence-free biosensor based on optical interferometry, and used it to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 96-well anti-PSA microarray. We have attained a 4 ng/ml detection limit in serum and have measured PSA concentrations in patient sera. The measured concentrations correlated well with enzyme-linked immunosorbent assay (ELISA) results. The measurement of PSA concentrations in high-level protein backgrounds suggests that the BioCD has a potential for clinical applications by removing the restriction of fluorescence-free biosensors from high-background applications.
登录
查看更多内容
影响因子：
12.6
作者：
Wee, KW;Kang, GY;Kim, TS
通讯作者：
Kim, TS
影响因子：
--
作者：
WADSWORTH, GR;OLIVEIRO, CJ
通讯作者：
OLIVEIRO, CJ
影响因子：
2.8
作者：
WANG, MC;PAPSIDORE, LD;CHU, TM
通讯作者：
CHU, TM
影响因子：
2.9
作者：
JIN, G;TENGVALL, P;ARWIN, H
通讯作者：
ARWIN, H
影响因子：
9.9
作者：
MALMSTEN, M
通讯作者：
MALMSTEN, M